Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital, discusses findings from part 2 of the phase 3 ENGOT-EN6-NSGO/GOG-3031/RUBY trial (NCT03981796) evaluating dostarlimab-gxly (Jemperli) in combination with chemotherapy followed by dostarlimab in combination with niraparib (Zejula) maintenance therapy in patients with primary advanced or recurrent endometrial cancer.